Search

Your search keyword '"Aragona G"' showing total 97 results
Start Over Author "Aragona G" Search Limiters Available in Library Collection
97 results on '"Aragona G"'

1. Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients

Author

Sciavilla, P, Strati, F, Di Paola, M, Modesto, M, Vitali, F, Cavalieri, D, Prati, G, Di Vito, M, Aragona, G, De Filippo, C, Mattarelli, P, Sciavilla P, Strati F, Di Paola M, Modesto M, Vitali F, Cavalieri D, Prati G.M, Di Vito M, Aragona G, De Filippo C, Mattarelli P., Sciavilla, P, Strati, F, Di Paola, M, Modesto, M, Vitali, F, Cavalieri, D, Prati, G, Di Vito, M, Aragona, G, De Filippo, C, Mattarelli, P, Sciavilla P, Strati F, Di Paola M, Modesto M, Vitali F, Cavalieri D, Prati G.M, Di Vito M, Aragona G, De Filippo C, and Mattarelli P.

Abstract

Studies so far conducted on irritable bowel syndrome (IBS) have been focused mainly on the role of gut bacterial dysbiosis in modulating the intestinal permeability, inflammation, and motility, with consequences on the quality of life. Limited evidences showed a potential involvement of gut fungal communities. Here, the gut bacterial and fungal microbiota of a cohort of IBS patients have been characterized and compared with that of healthy subjects (HS). The IBS microbial community structure differed significantly compared to HS. In particular, we observed an enrichment of bacterial taxa involved in gut inflammation, such as Enterobacteriaceae, Streptococcus, Fusobacteria, Gemella, and Rothia, as well as depletion of health-promoting bacterial genera, such as Roseburia and Faecalibacterium. Gut microbial profiles in IBS patients differed also in accordance with constipation. Sequence analysis of the gut mycobiota showed enrichment of Saccharomycetes in IBS. Culturomics analysis of fungal isolates from feces showed enrichment of Candida spp. displaying from IBS a clonal expansion and a distinct genotypic profiles and different phenotypical features when compared to HS of Candida albicans isolates. Alongside the well-characterized gut bacterial dysbiosis in IBS, this study shed light on a yet poorly explored fungal component of the intestinal ecosystem, the gut mycobiota. Our results showed a differential fungal community in IBS compared to HS, suggesting potential for new insights on the involvement of the gut mycobiota in IBS. Key points: • Comparison of gut microbiota and mycobiota between IBS and healthy subjects • Investigation of cultivable fungi in IBS and healthy subjects • Candida albicans isolates result more virulent in IBS subjects compared to healthy subjects.

Published
2021

2. The management of endoscopic retrograde cholangiopancreatography-related infections risk: results of an italian survey at regional level.

Author

Cennamo, V., Landi, S., Aragona, G., Colecchia, A., Conigliaro, R., Di Lorenzo, D., Di Marco, M., Fabbri, C., Falcone, P., Gaiani, F., Manno, M., Merighi, A., Mussetto, A., Peghetti, A., Sassateli, R., Solfrini, V., Zagari, R. M., Arena, R., Bertani, H., and Binda, C.

Subjects
ENDOSCOPIC retrograde cholangiopancreatography, MULTIDRUG resistance, IMMUNOSUPPRESSIVE agents, INTERNET surveys, CLINICAL trials
Abstract

Copyright of Annali di Igiene, Medicina Preventiva e di Comunità is the property of Societa Editrice Universo s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

6. Factors That Affect Adequacy of Colon Cleansing for Colonoscopy in Hospitalized Patients

Author

Fuccio, L., Frazzoni, L., Spada, Cristiano, Mussetto, A., Fabbri, Carlo, Manno, M., Aragona, G., Zagari, Rocco Maurizio, Rondonotti, E., Manes, G., Occhipinti, P., Cadoni, S., Bazzoli, F., Hassan, Cesare, Radaelli, F., Laterza, Lucrezia, Alemanni, L. V., Buttitta, F., Cirota, G., Cominardi, A., Impellizzeri, G., La Marca, M., Marasco, G., Metelli, F., Pierantoni, C., Sansone, V., Tamanini, G., Cesaro, Paola, Piccirelli, Stefania, Feletti, V., Triossi, O., Arena, Rosanna, Binda, C., Nicolini, G., Sbrancia, M., Trebbi, M., Cuffari, B., Soriani, P., Comparato, G., Prati, G. M., Reati, R., Corte, C. D., Liggi, M., Mura, D., Spada C. (ORCID:0000-0002-5692-0960), Fabbri C., Zagari R. M., Hassan C., Laterza L., Cesaro P., Piccirelli S., Arena R., Fuccio, L., Frazzoni, L., Spada, Cristiano, Mussetto, A., Fabbri, Carlo, Manno, M., Aragona, G., Zagari, Rocco Maurizio, Rondonotti, E., Manes, G., Occhipinti, P., Cadoni, S., Bazzoli, F., Hassan, Cesare, Radaelli, F., Laterza, Lucrezia, Alemanni, L. V., Buttitta, F., Cirota, G., Cominardi, A., Impellizzeri, G., La Marca, M., Marasco, G., Metelli, F., Pierantoni, C., Sansone, V., Tamanini, G., Cesaro, Paola, Piccirelli, Stefania, Feletti, V., Triossi, O., Arena, Rosanna, Binda, C., Nicolini, G., Sbrancia, M., Trebbi, M., Cuffari, B., Soriani, P., Comparato, G., Prati, G. M., Reati, R., Corte, C. D., Liggi, M., Mura, D., Spada C. (ORCID:0000-0002-5692-0960), Fabbri C., Zagari R. M., Hassan C., Laterza L., Cesaro P., Piccirelli S., and Arena R.

Abstract

Background & Aims: Hospitalization is associated with inadequate colon cleansing before colonoscopy. We aimed to identify factors associated to inadequate colon cleansing among inpatients, and to derive and validate a model to identify inpatients with inadequate cleansing. Methods: We performed a prospective observational study at 12 hospitals in Italy. Consecutive adult inpatients scheduled for colonoscopy for any indication were enrolled from February through May 2019 (derivation cohort, n = 1016) and from June through August 2019 (validation cohort, n = 508). Inadequate cleansing was defined as Boston bowel preparation scale scores below 2 in any colon segment. We performed multivariate logistic regression to identify factors associated with inadequate cleansing. Results: In the combined cohorts, 1032 patients (68%) had adequate colon cleansing. Physicians’ meetings to optimize bowel preparation (odds ratio [OR], 0.42; 95% CI, 0.27–0.65), written and oral instructions to patients (OR, 0.48; 95% CI, 0.36–0.65), admission to gastroenterology unit (OR, 0.71; 95% CI, 0.51–0.98), split-dose regimens (OR, 0.27; 95% CI, 0.20–0.35), a 1-liter polyethylene glycol-based bowel purge (OR, 0.39; 95% CI, 0.23—0.65), and 75% or more intake of bowel preparation (OR, 0.09; 95% CI, 0.05–0.15) significantly reduced odds of inadequate colon cleansing. Alternatively, bedridden status (OR, 2.14; 95% CI, 1.55–2.98), constipation (OR, 2.16; 95% CI, 1.55–3.0), diabetes mellitus (OR, 1.61; 95% CI, 1.18–2.20), use of anti-psychotic drugs (OR, 3.26; 95% CI, 1.62–6.56), and 7 or more days of hospitalization (OR, 1.02; 95% CI, 1.00–1.04) increased risk of inadequate colon cleansing. We developed a model to identify patients with inadequate cleaning using data from patients in the derivation cohort and tested it in the validation cohort. Calibration values were P = .218 for the discrimination cohort and P = .232 for the validation cohort. Discrimination values were c-statistic, 0.78 (95% C

Published
2021

7. The diagnostic yield of colonoscopy in hospitalized patients. An observational multicenter prospective study

Author

Frazzoni, L., Radaelli, F., Spada, Cristiano, Mussetto, A., Frazzoni, M., Laterza, Lucrezia, Rondonotti, E., La Marca, M., Zagari, Rocco Maurizio, Piccirelli, Stefania, Bazzoli, F., Fabbri, Carlo, Manno, M., Aragona, G., Manes, G., Occhipinti, P., Cadoni, S., Hassan, Cesare, Fuccio, L., Spada C. (ORCID:0000-0002-5692-0960), Laterza L., Zagari R. M., Piccirelli S., Fabbri C., Hassan C., Frazzoni, L., Radaelli, F., Spada, Cristiano, Mussetto, A., Frazzoni, M., Laterza, Lucrezia, Rondonotti, E., La Marca, M., Zagari, Rocco Maurizio, Piccirelli, Stefania, Bazzoli, F., Fabbri, Carlo, Manno, M., Aragona, G., Manes, G., Occhipinti, P., Cadoni, S., Hassan, Cesare, Fuccio, L., Spada C. (ORCID:0000-0002-5692-0960), Laterza L., Zagari R. M., Piccirelli S., Fabbri C., and Hassan C.

Abstract

Background: Colonoscopy demands a considerable amount of resources, and little is known about its diagnostic yield among inpatients. Aims: To assess indications, diagnostic yield and findings of colonoscopy for inpatients, and to identify risk factors for relevant findings and cancer. Methods: Multicentre, prospective, observational study including 12 hospitals. Consecutive adult inpatients undergoing colonoscopy were evaluated from February through November 2019. Results: 1,302 inpatients underwent colonoscopy. Diagnostic yield for relevant findings and cancer was 586 (45%) and 112 (8.6%), respectively. Adequate colon cleansing was achieved in 896 (68.8%) patients. Split-dose/same-day regimen was adopted in 847 (65%) patients. Factors associated to relevant findings were age ≥70 years (RR 1.32), male gender (RR 1.11), blood loss (RR 1.22) and adequate cleansing (RR 1.63). Age ≥70 years (RR 2.08), no previous colonoscopy (RR 2.69) and split-dose/same-day regimen (RR 1.59) significantly increased cancer detection. Implementing adequate cleansing and split-dose/same-day regimen in all patients would increase the diagnostic yield for any relevant findings and cancer from 43% to 70% and from 6% to 10%, respectively. Conclusion: Relevant colorectal diseases and cancer were frequent among inpatients. Factors associated with detection of relevant findings were identified. Adequate colon cleansing and split-dose/same-day regimen significantly increased colonoscopy diagnostic yield.

Published
2021

8. Endoscopy units and the COVID-19 Outbreak: A Multi-Center Experience from Italy

Author

Repici, A, Pace, F, Gabbiadini, R, Colombo, M, Hassan, C, Dinelli, M, Maselli, R, Spadaccini, M, Mutignani, M, Gabbrielli, A, Signorelli, C, Spada, C, Leoni, P, Fabbri, C, Segato, S, Gaffuri, N, Mangiavillano, B, Radaelli, F, Salerno, R, Bargiggia, S, Maroni, L, Benedetti, A, Occhipinti, P, De Grazia, F, Ferraris, L, Cengia, G, Greco, S, Alvisi, C, Scarcelli, A, De Luca, L, Cereatti, F, Testoni, Pa, Mingotto, R, Aragona, G, Manes, G, Beretta, P, Amvrosiadis, G, Cennamo, V, Lella, F, Missale, G, Lagoussis, P, Triossi, O, Giovanardi, M, De Roberto, G, Canto, P, Buscarini, E, Anderloni, A, Carrara, S, Fugazza, A, Galtieri, Pa, Pellegatta, G, Antonelli, G, Rosch, T, and Sharma, P

Subjects
Coronavirus, Pandemic, Survery, COVID-19, Endoscopy
Published
2020

9. Endoscopy Units and the Coronavirus Disease 2019 Outbreak: A Multicenter Experience From Italy

Author

Repici, A., Pace, F., Gabbiadini, R., Colombo, M., Hassan, Cesare, Dinelli, M., Maselli, R., Spadaccini, M., Mutignani, Massimiliano, Gabbrielli, A., Signorelli, C., Spada, Cristiano, Leoni, Paola, Fabbri, Carlo, Segato, S., Gaffuri, N., Mangiavillano, B., Radaelli, F., Salerno, R., Bargiggia, S., Maroni, L., Benedetti, A., Occhipinti, P., De Grazia, F., Ferraris, L., Cengia, G., Greco, Sara, Alvisi, C., Scarcelli, A., De Luca, L., Cereatti, F., Testoni, P. A., Mingotto, R., Aragona, G., Manes, G., Beretta, P., Amvrosiadis, G., Cennamo, Vincenzo, Lella, F., Missale, G., Lagoussis, P., Triossi, O., Giovanardi, Mattia, De Roberto, G., Cantu, P., Buscarini, E., Anderloni, A., Carrara, S., Fugazza, A., Galtieri, P. A., Pellegatta, G., Antonelli, G., Rosch, T., Sharma, P., Hassan C., Mutignani M. (ORCID:0000-0002-1272-4888), Spada C. (ORCID:0000-0002-5692-0960), Leoni P., Fabbri C., Greco S., Cennamo V., Giovanardi M., Repici, A., Pace, F., Gabbiadini, R., Colombo, M., Hassan, Cesare, Dinelli, M., Maselli, R., Spadaccini, M., Mutignani, Massimiliano, Gabbrielli, A., Signorelli, C., Spada, Cristiano, Leoni, Paola, Fabbri, Carlo, Segato, S., Gaffuri, N., Mangiavillano, B., Radaelli, F., Salerno, R., Bargiggia, S., Maroni, L., Benedetti, A., Occhipinti, P., De Grazia, F., Ferraris, L., Cengia, G., Greco, Sara, Alvisi, C., Scarcelli, A., De Luca, L., Cereatti, F., Testoni, P. A., Mingotto, R., Aragona, G., Manes, G., Beretta, P., Amvrosiadis, G., Cennamo, Vincenzo, Lella, F., Missale, G., Lagoussis, P., Triossi, O., Giovanardi, Mattia, De Roberto, G., Cantu, P., Buscarini, E., Anderloni, A., Carrara, S., Fugazza, A., Galtieri, P. A., Pellegatta, G., Antonelli, G., Rosch, T., Sharma, P., Hassan C., Mutignani M. (ORCID:0000-0002-1272-4888), Spada C. (ORCID:0000-0002-5692-0960), Leoni P., Fabbri C., Greco S., Cennamo V., and Giovanardi M.

Abstract

Up to 20% of health care personnel (HCP) were found to be infected with coronavirus disease (COVID-19)1 in the outbreak in northern Italy.2 Recommendations on patient and HCP protection have been made, such as postponing procedures, triage, use of personal protective equipment (PPE), and creation of differentiated in-hospital pathways.3,4 However, several barriers against the adoption of these strategies exist, including cultural factors and shortages of medical resources; therefore, there are few reports of real-world experiences and outcomes with their adoption.5 The aim of this survey was to investigate the burden of COVID-19 on endoscopic activity in a high-risk area of COVID-19 outbreak, approaches to evaluating patients, adoption and compliance of HCP with protective measures, and initial possible viral transmission outcomes from endoscopy units within a large, community-based setting (both between patients and HCP and between HCP).

Published
2020

10. 1L- vs. 4L-Polyethylene glycol for bowel preparation before colonoscopy among inpatients: A propensity score-matching analysis

Author

Frazzoni, L., Spada, Cristiano, Radaelli, F., Mussetto, A., Laterza, Lucrezia, La Marca, M., Piccirelli, Stefania, Cortellini, F., Rondonotti, E., Paci, V., Bazzoli, F., Fabbri, Carlo, Manno, M., Aragona, G., Manes, G., Occhipinti, P., Cadoni, S., Zagari, Rocco Maurizio, Hassan, Cesare, Fuccio, L., Spada C. (ORCID:0000-0002-5692-0960), Laterza L., Piccirelli S., Fabbri C., Zagari R. M., Hassan C., Frazzoni, L., Spada, Cristiano, Radaelli, F., Mussetto, A., Laterza, Lucrezia, La Marca, M., Piccirelli, Stefania, Cortellini, F., Rondonotti, E., Paci, V., Bazzoli, F., Fabbri, Carlo, Manno, M., Aragona, G., Manes, G., Occhipinti, P., Cadoni, S., Zagari, Rocco Maurizio, Hassan, Cesare, Fuccio, L., Spada C. (ORCID:0000-0002-5692-0960), Laterza L., Piccirelli S., Fabbri C., Zagari R. M., and Hassan C.

Abstract

Background: Inpatients are at risk for inadequate colon cleansing. Experts recommend 4L-polyethylene-glycol (PEG) solution. A higher colon cleansing adequacy rate for a hyperosmolar 1L-PEG plus ascorbate prep has been recently reported. Aims: We aimed to determine whether 1L-PEG outperforms 4L-PEG among inpatients. Methods: post-hoc analysis of a large Italian multicenter prospective observational study among inpatients (QIPS study). We performed a propensity score matching between 1L-PEG and 4L-PEG group. The primary outcome was the rate of adequate colon cleansing as assessed by unblinded endoscopists through Boston scale. Secondary outcome was the safety profile. Results: Among 1,004 patients undergoing colonoscopy, 724 (72%) were prescribed 4L-PEG and 280 (28%) 1L-PEG. The overall adequate colon cleansing rate was 69.2% (n = 695). We matched 274 pairs of patients with similar distribution of confounders. The rate of patients with adequate colon cleansing was higher in 1L-PEG than in 4L-PEG group (84.3% vs. 77.4%, p = 0.039). No different shift in serum concentration of electrolytes (namely Na+, K+, Ca2+), creatinine and hematocrit were observed for both preparations. Conclusion: We found a higher rate of adequate colon cleansing for colonoscopy with the 1L-PEG bowel prep vs. 4L-PEG, with apparent similar safety profile, among inpatients. A confirmatory randomized trial is needed. (ClinicalTrials.gov no: NCT04310332)

Published
2020

11. Potent in vitro activity of citrus aurantium essential oil and vitis vinifera hydrolate against gut yeast isolates from irritable bowel syndrome patients—the right mix for potential therapeutic use

Author

Di Vito, Maura, Grazia Bellardi, M., Sanguinetti, Maurizio, Mondello, F., Girolamo, A., Barbanti, L., Garzoli, S., Sabatino, M., Ragno, R., Vitali, Alberto, Palucci, Ivana, Posteraro, Brunella, Gasbarrini, Antonio, Maria Prati, G., Aragona, G., Mattarelli, P., Bugli, Francesca, Di Vito M. (ORCID:0000-0002-2991-0855), Sanguinetti M. (ORCID:0000-0002-9780-7059), Vitali A., Palucci I., Posteraro B. (ORCID:0000-0002-1663-7546), Gasbarrini A. (ORCID:0000-0002-7278-4823), Bugli F. (ORCID:0000-0001-9038-3233), Di Vito, Maura, Grazia Bellardi, M., Sanguinetti, Maurizio, Mondello, F., Girolamo, A., Barbanti, L., Garzoli, S., Sabatino, M., Ragno, R., Vitali, Alberto, Palucci, Ivana, Posteraro, Brunella, Gasbarrini, Antonio, Maria Prati, G., Aragona, G., Mattarelli, P., Bugli, Francesca, Di Vito M. (ORCID:0000-0002-2991-0855), Sanguinetti M. (ORCID:0000-0002-9780-7059), Vitali A., Palucci I., Posteraro B. (ORCID:0000-0002-1663-7546), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Bugli F. (ORCID:0000-0001-9038-3233)

Abstract

Background: Irritable bowel syndrome (IBS) is a functional disorder without any pathological alteration, in which the alterations of the Candida/Saccharomyces ratio of the gut microbiota, the balance of pro and anti-inflammatory cytokines and the brain-gut-microbiome axis are important for the development and progression of IBS. The aim of the study was to identify natural products, including essential oils or hydrolates, which were contextually harmless for the gut beneficial strains (e.g. Saccharomyces spp.) but inhibitory for the pathogenic ones (Candida spp.). Methods: The effectiveness of 6 essential oils and 2 hydrolates was evaluated using microbiological tests, carried out on 50 clinical isolates (Candida, Saccharomyces and Galattomyces species) and 9 probiotic strains (Saccharomyces cerevisiae, Lactobacillus species, Akkermansia muciniphila and Faecalibacterium prausnitzii) and immunological and antioxidant assays. Results: The study led to a mixture based on a 1/100 ratio of Citrus aurantium var. amara essential oil/Vitis vinifera cv Italia hydrolate able to contextually reduce, in a concentration-dependent manner, the ability of Candida species to form hyphal filaments and have an interesting immunomodulatory and anti-oxidant action. This mixture can potentially be useful in the IBS treatment promoting the restoration of the intestinal microbial and immunological balance.

Published
2020

12. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study

Author

DI MARIO, F., ARAGONA, G., DAL BÓ, N., CAVALLARO, L., MARCON, V., OLIVIERI, P., BENEDETTI, E., ORZÈS, N., MARIN, R., TAFNER, G., CHILOVI, F., DE BASTIANI, R., FEDRIZZI, F., FRANCESCHI, M., SALVAT, M. H., MONICA, F., PIAZZI, L., VALIANTE, F., VECCHIATI, U., CAVESTRO, G. M., COMPARATO, G., IORI, V., MAINO, M., LEANDRO, G., PILOTTO, A., RUGGE, M., and FRANZÈ, A.

Published
2006

15. Use of mesalazine in diverticular disease

Author

Di Mario F, Comparato G, Fanigliulo L, Aragona G, Cavallaro LG, Franzé A., CAVESTRO , GIULIA MARTINA, Di Mario, F, Comparato, G, Fanigliulo, L, Aragona, G, Cavallaro, Lg, Cavestro, GIULIA MARTINA, and Franzé, A.

Published
2006

16. Efficacy of mesalazine in the treatment of symptomatic diverticular disease

Author

Di Mario F, Aragona G, Leandro G, Comparato G, Fanigliulo L, Cavallaro LG, Iori V, Maino M, Moussa AM, Gnocchi A, Mazzocchi G, Franzé A., CAVESTRO , GIULIA MARTINA, Di Mario, F, Aragona, G, Leandro, G, Comparato, G, Fanigliulo, L, Cavallaro, Lg, Cavestro, GIULIA MARTINA, Iori, V, Maino, M, Moussa, Am, Gnocchi, A, Mazzocchi, G, and Franzé, A.

Published
2005

18. Bovine lactoferrin as a rescure treatment for Helicobacter pylori infection: results of a multicenter study

Author

DI MARIO F, DAL B. N, ARAGONA G, MARCON V, OLIVIERI PG, MARIN R, DE BASTIANI R, PIAZZI L, CHILOVI F, FEDRIZZI F, TAFNER G, MONICA F, HERAS H, GERMAN B, FANIGLIULO L, MAZZOCCHI G, CAVALLARO LG, MAINO M, FRANZ A., CAVESTRO , GIULIA MARTINA, DI MARIO, F, DAL B., N, Aragona, G, Marcon, V, Olivieri, Pg, Marin, R, DE BASTIANI, R, Piazzi, L, Chilovi, F, Fedrizzi, F, Tafner, G, Monica, F, Heras, H, German, B, Fanigliulo, L, Mazzocchi, G, Cavallaro, Lg, Maino, M, Cavestro, GIULIA MARTINA, and Franz, A.

Published
2005

19. Efficacy of bovine lactoferrin fot Helicobacter pylori eradication: results of a multicenter study

Author

DI MARIO F, DA B. N, ARAGONA G, MARCON V, OLIVIERI PG, MARIN R, DE BASTIANI R, PIAZZI L, CHILOVI F, FEDRIZZI F, TAFNER G, VECCHIATI U, MONICA F, H, FRANCESCHI M, ORZES N, BENEDETTI E, FANIGLIULO L, MAZZOCCHI G, CAVALLARO LG, MAINO M, IORI V, FRANZ A., CAVESTRO , GIULIA MARTINA, DI MARIO, F, DA B., N, Aragona, G, Marcon, V, Olivieri, Pg, Marin, R, DE BASTIANI, R, Piazzi, L, Chilovi, F, Fedrizzi, F, Tafner, G, Vecchiati, U, Monica, F, H, Franceschi, M, Orzes, N, Benedetti, E, Fanigliulo, L, Mazzocchi, G, Cavallaro, Lg, Maino, M, Iori, V, Cavestro, GIULIA MARTINA, and Franz, A.

Published
2005

20. Recovery of gastric function after H. pylori eradication in subjects with body atrophic gastritis: a prospective four years study

Author

MOUSSA AM, DALB N, CARUANA P, CAVALLARO LG, ARAGONA G, LIATOPOULOU S, IORI V, MERLI R, MAINI A, GNOCCHI A, PILOTTO A, FRANZ A, DI MARIO F., CAVESTRO , GIULIA MARTINA, Moussa, Am, Dalb, N, Caruana, P, Cavallaro, Lg, Aragona, G, Liatopoulou, S, Cavestro, GIULIA MARTINA, Iori, V, Merli, R, Maini, A, Gnocchi, A, Pilotto, A, Franz, A, and DI MARIO, F.

Published
2003

21. Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer

Author

FRANZ A, NERVI G, COMPARATO G, MOUSSA AM, DE LISI V, CARLONI C, LIATOPOULOU S, ARAGONA G, CAVALLARO LG, IORI V, MAINO M, MARCUCCI F, DI MARIO F., CAVESTRO , GIULIA MARTINA, Franz, A, Nervi, G, Comparato, G, Moussa, Am, DE LISI, V, Carloni, C, Liatopoulou, S, Aragona, G, Cavallaro, Lg, Cavestro, GIULIA MARTINA, Iori, V, Maino, M, Marcucci, F, and DI MARIO, F.

Published
2003

22. Effect of H. pylori eradication in dyspeptic subjects: a prospective seven years study

Author

STEFANI N, DAL B. N, MAINO M, IORI V, CAVALLARO LG, LEANDRO G, PILOTTO A, ARAGONA G, ALTAVILLA N, BOSI S, VENERITO M, FRANZ A, DI MARIO F., CAVESTRO , GIULIA MARTINA, Stefani, N, DAL B., N, Cavestro, GIULIA MARTINA, Maino, M, Iori, V, Cavallaro, Lg, Leandro, G, Pilotto, A, Aragona, G, Altavilla, N, Bosi, S, Venerito, M, Franz, A, and DI MARIO, F.

Published
2003

23. A new marker for monitoring alcohol abuse? A pilot study on heavy drinkers

Author

INGEGNOLI A, BIASINI E, BONI I, ALTAVILLA N, LANDINI F, MERLI R, IORI V, ARAGONA G, CAVALLARO LG, MAINO M, FRANZ A, VESCOVI P, DI MARIO F., CAVESTRO , GIULIA MARTINA, Ingegnoli, A, Biasini, E, Boni, I, Altavilla, N, Landini, F, Merli, R, Iori, V, Cavestro, GIULIA MARTINA, Aragona, G, Cavallaro, Lg, Maino, M, Franz, A, Vescovi, P, and DI MARIO, F.

Published
2003

24. Lactoferrin in a 1-week triple therapy for eradication of H. pylori

Author

ARAGONA G, DI MARIO F, CAVALLARO GL, IORI V, COMPARATO G, LEANDRO G, MUZZETTO P, PILOTTO A, FRANZ A., CAVESTRO , GIULIA MARTINA, Aragona, G, DI MARIO, F, Cavallaro, Gl, Cavestro, GIULIA MARTINA, Iori, V, Comparato, G, Leandro, G, Muzzetto, P, Pilotto, A, and Franz, A.

Published
2003

27. Gastropanel as screening of gastric atrophy in primary care

Author

GERMANA B, LIATOPOULOU S, COMPARATO G, MOUSSA AM, CARLONI C, LECIS P, BERTIATO B, DOGLIONI C, ARAGONA G, CAVALLARO LG, IORI V, MERLI R, BERTOLINI S, CARUANA P, BIEDO FC, DI MARIO F., CAVESTRO , GIULIA MARTINA, Germana, B, Liatopoulou, S, Comparato, G, Moussa, Am, Carloni, C, Lecis, P, Bertiato, B, Doglioni, C, Aragona, G, Cavallaro, Lg, Cavestro, GIULIA MARTINA, Iori, V, Merli, R, Bertolini, S, Caruana, P, Biedo, Fc, and DI MARIO, F.

Published
2003

29. Serum pepsinogen II as a biomarker in management of H. pylori infection

Author

MOUSSA AM, CAVALLARO LG, CARUANA P, MERLI R, IORI V, DALB N, ARAGONA G, BERTOLINI S, SERENI G, PRATI B, COLLA G, FRANZ A, DI MARIO F., CAVESTRO , GIULIA MARTINA, Moussa, Am, Cavallaro, Lg, Caruana, P, Merli, R, Iori, V, Cavestro, GIULIA MARTINA, Dalb, N, Aragona, G, Bertolini, S, Sereni, G, Prati, B, Colla, G, Franz, A, and DI MARIO, F.

Published
2003

34. Relationship between direct and indirect methods for diagnosis of H.pylori infection

Author

MOUSSA A, IORI V, ARAGONA G, SEGHINI P, CERATI E, CAMPI L, COMPARATO G, LEANDRO G, BATTAGLIA G, DAL B. N, FRANZ A, DI MARIO F., CAVESTRO , GIULIA MARTINA, Moussa, A, Iori, V, Aragona, G, Seghini, P, Cerati, E, Campi, L, Cavestro, GIULIA MARTINA, Comparato, G, Leandro, G, Battaglia, G, DAL B., N, Franz, A, and DI MARIO, F.

Published
2002

35. Lactoferrin: mechanism of action, clinical significance and therapeutic

Author

CAVESTRO , GIULIA MARTINA, IORI V., DAL BO N., FRANZE A., INGEGNOLI A.V., MANTOVANI N., PILOTTO A., DI MARIO F., ARAGONA G., ALTAVILLA N., BERTELE\' A., BORGHI L., Cavestro, GIULIA MARTINA, Iori, V., DAL BO, N., Franze, A., Ingegnoli, A. V., Mantovani, N., Pilotto, A., DI MARIO, F., Aragona, G., Altavilla, N., Bertele\', A., and Borghi, L.

Published
2002

39. One-week H. pylori eradication therapy rabeprazole 20mg b.i.d. Vs 10mg b.i.d

Author

MOUSSA AM, INGEGNOLI A, SEGHINI P, ARAGONA G, DAL B. N, ORSI P, PILOTTO A, LEANDRO G, RUGGE M, DI MARIO F., CAVESTRO , GIULIA MARTINA, Moussa, Am, Ingegnoli, A, Seghini, P, Aragona, G, Cavestro, GIULIA MARTINA, DAL B., N, Orsi, P, Pilotto, A, Leandro, G, Rugge, M, and DI MARIO, F.

Published
2001

44. Role of gut microflora and probiotic effects in the irritable bowel syndrome

Author

Fanigliulo, L., Comparato, G., Aragona, G., Cavallaro, L., Iori, V., Maino, M., Giulia Martina Cavestro, Soliani, P., Sianesi, M., Franzè, A., Di Mario, F., Fanigliulo, Libera, Comparato, Giuseppe, Aragona, Giovanni, Cavallaro, Luca, Iori, Veronica, Maino, Marta, Cavestro, Giulia Martina, Soliani, Paolo, Sianesi, Mario, Franzè, Angela, and Di Mario, Francesco

Subjects
Irritable bowel syndrome, Poorly absorbable antibiotic, Medicine (all), Intestinal microflora, Probiotic strain, Stool frequency, Small intestinal bacterial overgrowth
Abstract

Background. Even though the cause of irritable bowel sindrome (IBS) is not yet known, alterations of the intestinal microflora may be important in its pathogenesis. Aim. To evaluate the efficacy of rifaximine alone or in association with the probiotic strain of Bifidobacterium longum W11 in reducing symptoms in patients with IBS. Methods. We performed a monocentric, prospective, randomized open trial including 70 patients randomized in to two groups: Group A (41 patients) receiving rifaximin 200 (2 cp bid for ten days in a month) followed by a formulation of the probiotic strain of Bifidobacterium longum W11(one granulated suspension for 6 days on alternate weeks) and Group B (29 patients) receiving only rifaximin 200 (2 cp bid for ten days in a month). The clinical evaluation was performed at admission and after 2-months, taking into account the method of visual analogous. Results. At the 2-month follow-up, Group A patients reported a greater improvement of symptoms compared to patients in group B (p = 0.010) even if the physician's opinion at T1 did not confirm these results (p = 0.07). Conclusion. The increased colonisation by Bifidobacterium longum W11, after the cyclic administration of rifaximin, which eradicates the bacterial over-growth of the small intestine, may reduce symptoms, especially those related to bowel habit and stool frequency in patients with IBS. The abnormalities observed in the colonic flora of IBS suggest, in fact, that a probiotic approach will ultimately be justified. © Mattioli 1885.

45. Relationship between direct and indirect methods for diagnosis of H. pylori infection.

Author

Moussa, A.M., Iori, V., Aragona, G., Seghini, P., Cerati, E., Campi, L., Cavestro, G.M., Comparato, G., Leandro, G., Battaglia, G., Dal Bò, N., Franzè, A., and Di Mario, F.

Subjects
HELICOBACTER pylori infections, PEPSINOGEN, BACTERIAL diseases, DIAGNOSIS
Abstract

Background: Helicobacter pylori stool antigen test (HpSA) is a usefull,non-invasive tool for diagnosis and for the check of the eradication after therapy, in Helicobacter pylori (Hp) infection. Serum pepsinogen II (sPGII) levels were found increased during Hp infection mostly due to the antrum. Aim: to evaluate the relationship between sPGII levels and Hp status (first diagnosis of infection and post-eradication control). Patients and Methods: Hp status was assessed by means of HpSA. 55 consecutive patients were studied. Group A (36 pts: 20 female, 16 males; mean age: 47; range: 22-77) with unknown Hp status were tested for the presence of Hp by means of HpSA (Meridian, Milano, Italy); group B (19 pts: 10 females; 9 males; mean age 50; range 25-80) patients after Hp eradication in witch HpSA was used to assess the efficacy of eradication therapy. In all patients, sPGII (Biohit, Helsinky Finland) was determined by means of serum ELISA determination. Results: In group A, 22 patients resulted Hp-ve, 8 of them showed sPGII (mean value 28.1 µg/dL, range 21-25) greater than normal values; 14 patients resulted positive for Hp infection, 8 of these showed sPGII (mean value 19.8 range 11-30) greater than normal values. There was no significative difference between Hp+ve patients and Hp-ve patients. In group B, 13 patients resulted negative for Hp infection, 4 of these showed sPGII (mean value 16.5 range 11-31) greater than normal values; 6pts. resulted Hp+ve infection, 5 of these showed sPGII (mean value 20.4 range 11-30) greater than normal values; there was significative difference (p = 0.05) between Hp+ve patients and Hp-ve patients. Conclusion: serum pepsinogen II levels remain high in Hp+ve patients in comparison with Hp-ve patients in post-eradication assessment. Both HpSA and sPGII can be used as non invasive tests to evaluate Hp eradication and the consequent changes in gastric inflammation pattern. [ABSTRACT FROM AUTHOR]

Published
2002

46. Serum pepsinogens and sucrose test in Helicobacter pylori related gastritis.

Author

Ingegnoli, A., Moussa, A.M., Altavilla, N., Seghini, P., Cerati, E., Mantovani, N., Aragona, G., CAruana, P., Cavestro, G.M., Leandro, G., Dal Bò, N., and Di Mario, F.

Subjects
HISTOLOGY, HELICOBACTER pylori, GASTRITIS, GASTRIC mucosa
Abstract

Background: Histology is still considered the golden standard for the diagnosis of H. pylori associated chronic gastritis and to evaluate the gastric mucosal damage. Serum pepsinogens I (sPGI)and II (sPGII), and gastric permeability investigated by oral sucrose test were found alterated in chronic superficial and deep gastritis as well of in presence of atrophy. Aim: To assess the integrity of gastric mucosa by two non-invasive tests: serum pepsinogen levels and oral sucrose test, and to investigate its relationship with histological findings. Patients and Methods: A series of 24 consecutive out patients (12 females, 12 males; mean age 42 years, range 18-81) observed at our department for upper gastrointestinal symptoms were enrolled. All patients were submitted to upper gastrointestinal endoscopy with biopsies examined by one patologist according to the Updated Sydney System classification, and performed oral sucrose test using 40 mg in 100 ml of water; serum samples were analysed using panel test including of EIA assays for sPGI and sPGII (Biohit, Helsinki, Finland). In first time, the patients were divided in Hp+ve and Hp -ve group and in second time in three groups:1. normal histology,2. superficial gastritis,3. focal or diffuse atrophic gastritis. Results: Fifteen patients resulted Hp +ve;a statically significant difference was found between sPGI, sPGII and sucrose in Hp+ve patients compared with Hp-ve ones (sPGI 147.7 ± 52.0 vs 80.0±36.4 p=0.0006; sPGII 16.8±9.0 vs 7.4±3.5 p=.007, sucrose 0.39±0.39 vs 0.07±0.006 p=0.007). A statically significant difference had been found for sucrose test singling out the patients according to different hystological severity of damage;normal histology (7 patients): sucrose 0.07±0.07; superficial gastritis (10 patients): 0.34±0.41 and atrophic gastritis (7 patients): 0.37±0.39; p=0.06. Conclusions: Serum pepsinogen I and II and sucrose test could be proposed as... [ABSTRACT FROM AUTHOR]

Published
2002

47. Potential use of lactoferrin in a 7 days triple therapy for Helicobacter pylori eradication: preliminary results.

Author

Di Mario, F., Aragona, G., Dal Bò, N., Ingegnoli, A., Cavestro, G.M., Moussa, A.M., Iori, V., Leandro, G., Pilotto, A., and Franzè, A.

Subjects
*LACTOFERRIN, *BACTERIAL diseases, TREATMENT of helicobacter pylori infections
Abstract

Background: One-week triple therapy is the most frequently recommended treatment for Helicobacter pylori infection. Eradication rate is satisfactory, nevertheless is advisable to look for more effective therapies. Our aim was to test the efficacy of a standard triple therapy plus bovin lactoferrin in the eradication of Helicobacter pylori infection. Materials and Methods: 74 Helicobacter pylori positive patients were consecutively enrolled in a 7-days triple therapy study with rabeprazole, clarithromycin, tinidazole, lactoferrin (group A) or rabeprazole, clarithromycin, tinidazole (group B), or 10 days therapy with rabeprazole, clarithromycin, tinidazole (group C). Helicobacter pylori status was assessed 8 weeks after the end of the treatment by means of C13-Urea breath test or Helicobacter pylori Stool Antigen-test. Results: The 7-days treatment including lactoferrin (Group A), was successful in 100% (24/24 pts.) of the patients, Group B presented an eradication rate of 76.9% (20/26pts.) and Group C of 70.8% (17/24pts.). Considering the three groups, a significative difference (p = 0.0067) was found with significative differences between group A vs. group B (p = 0.023) and group A vs. group C (p = 0.022). No differences were found between group B and group C (p = 1.00). Conclusion: These results suggest that lactoferrin could be a new, effective agent to assist the antimicrobials in the eradication of H. pylori. This schedule, could be proposed for more wide trials in Helicobacter pylori eradication strategy, focusing on the excellent preliminary cure rate, the good compliance to the schedule, and the relatively low price of lactoferrin for full treatment. [ABSTRACT FROM AUTHOR]

Published
2002

48. Topography of gastric damage in H. pylori infection: evaluation by serum pepsinogens levels.

Author

Cavallaro, L.G., Moussa, A.M., Seghini, P., Aragona, G., Iori, V., Cavestro, G.M., Dal Bò, N., Pilotto, A., Leandro, G., and Di Mario, F.

Subjects
HELICOBACTER pylori infections, GASTRIC mucosa, PEPSINOGEN
Abstract

Background: Helicobacter pylori infection is characterized by activity in gastric mucosa. Serum pepsinogen I (sPGI) and II (sPGII) have been proposed a "serological biopsies "of gastric mucosa and resulted altered in Hp infection. Aim: To evaluate sPGI and sPGII levels in relation to the topography of activity-induced Hp infection in gastric mucosa. Patients and methods: Sixty-six consecutive out patients (36 F, 30 M mean age 45.7 years, range 18-88) referred to our department for dispeptic symptoms were studied. In all patients, blood samples were taken to evaluate sPGI and sPGII levels (Biohit, Helsinki, Finland); each subject performed upper gastrointestinal endoscopy with five biopsies (2 antrum, 1 angulus, 2 corpus); gastritis was scored according to the updated Sydney System. We designed the topography of activity as antral-predominant activity (APA, antrum>corpus),diffused activity (DA antrum = corpus) and corpus predominant activity (CPA, corpus>antrum). Results: Thirty patients were found Hp+ve and 36 Hp-ve. The topographical distribution of activity was described as APA in 14/30 of patients, DA in 12/30 and CPA in 4/30.Mean sPGII levels in Hp+ve were significantly higher compared with Hp-ve group (Hp-ve group: 9,5 µg/dl; APA: 14,2µg/dl; DA 22 µg/dl, p=0.0002). No differences was found comparing Hp-ve group with CPA: 18 µg/dl p=0.02. In the Hp+ve group, mean sPGII levels were higher in DA: 22 µg/dl vs APA: 14,2 µg/dl); without significant differences. Mean sPGI levels in Hp+ve were significantly higher in APA: 166 µg/dl and DA: 150 µg/dl group compared to Hp-ve group: 101 µg/dl p=0.0003; sPGI levels result significantly lower in CPA: 71.5 µg/dl group than in DA p=0.0003. Conclusion: These data confirmed that sPGII could be proposed as marker of activity induced by Hp infection; low levels of sPGI and sPGII can explain the presence of initial signs of mucosal damage. [ABSTRACT FROM AUTHOR]

Published
2002

49. Influence of different epidemiological, pharmacological and biological factors of serum pepsinogen levels.

Author

Di Mario, F., Seghini, P., Moussa, A.M., Iori, V., Aragona, G., Cavestro, G.M., Dal Bò, N., Maino, M., Mantovani, N., Ingegnoli, A., Pilotto, A., and Franzè, A.

Subjects
PEPSINOGEN, BIOPSY, GASTRIC mucosa
Abstract

Background: Serum pepsinogens I (sPGI) and II (sPGII) have been proposed from the early '80 as "serological biopsy" of gastric mucosa. Recently, the use of ELISA method instead of the radioimmunoassay labelling widely contributed to the spread of the test for the assessment of upper gastrointestinal disease, and particularly gastritis. Methods: Four hundred and eighteen consecutive subjects (M190;F228, mean age 52, range15-102) admitted at the gastroenterological unit of Parma University as outpatients for an uninvestigated dyspepsia undergone a blood sample for serum pepsinogen determination (sPGI and sPGII; Biohit, Helsinki, Finland). For each patient the following parameters were taken into account in order to determine possible influence on such the two tests (sPGI and sPGII): sex, age, Helicobacter pylori status (assessed by means of HpSA fecal antigen) in 121 subjects, PPIs therapy, NSAIDs use, smoking habit and alcohol consumption. As normal values of sPGI and sPGII were considered 25-100 and 2-10 µg/l respectively. Results: Sex: male, sPGI 140.7 ± 83.1; sPGII 17.5 ± 22.1. Female, sPGI 134.8 ± 81.1; sPGII 16.2 ± 3.7. Age ≤50: sPGI 129.3 ± 73.8; sPGII 13.9 ± 1.7. Age >50:sPGI 144.8 ± 88.2; sPGII 19.4 ± 22.9. PPIs use: sPGI 184.2 ± 96.9; sPGII 20.9±14.7. No PPIs: sPGI 115.3±64.3; sPGII 13.6 ± 12.3 (p<0.001). HP+ve: sPGI 137 ± 76; sPGII 16 ± 9; HP-ve: sPGI 98 ± 48; sPGII 9 ± 4. NSAIDs(+): sPGI 140.5 ± 72.3; sPGII 15.3 ± 15.4. NSAIDs(-): sPGI 120.9 ± 65.5; sPGII15.2 ± 14.5. Alcohol(+): sPGI 163.9 ± 91.2; sPGII 16.9 ±13.4. Alcohol(-): sPGI 145.3 ± 83.1; sPGII 17.3 ±15.0. Smokers: sPGI 144.8 ± 75.9; sPGII 15.5 ± 9.6. Not smokers: sPGI 143.3 ± 91.0; sPGII 16.0 ± 75.9. Conclusions: sPGI and sPGII levels are mostly influenced by the Hp status as well as the... [ABSTRACT FROM AUTHOR]

Published
2002

50. Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients

Author

Piero Sciavilla, Paola Mattarelli, Monica Di Paola, G. M. Prati, Francesco Vitali, Monica Marianna Modesto, Giovanni Aragona, Maura Di Vito, Duccio Cavalieri, Francesco Strati, Carlotta De Filippo, Sciavilla, P, Strati, F, Di Paola, M, Modesto, M, Vitali, F, Cavalieri, D, Prati, G, Di Vito, M, Aragona, G, De Filippo, C, Mattarelli, P, Sciavilla, Piero, Strati, Francesco, Di Paola, Monica, Modesto, Monica, Vitali, Francesco, Cavalieri, Duccio, Prati, Gian Maria, Di Vito, Maura, Aragona, Giovanni, De Filippo, Carlotta, and Mattarelli, Paola

Subjects
Mycobiota, Gut microbiota, Gut flora, Applied Microbiology and Biotechnology, Microbiology, Feces, 03 medical and health sciences, 0302 clinical medicine, Gut mycobiota, medicine, Humans, Candida albicans, Ecosystem, Irritable bowel syndrome, Applied Genetics and Molecular Biotechnology, 030304 developmental biology, 0303 health sciences, Intestinal permeability, biology, Fusobacteria, General Medicine, medicine.disease, biology.organism_classification, Gastrointestinal Microbiome, Quality of Life, Dysbiosis, 030211 gastroenterology & hepatology, Roseburia, Biotechnology
Abstract

Abstract Studies so far conducted on irritable bowel syndrome (IBS) have been focused mainly on the role of gut bacterial dysbiosis in modulating the intestinal permeability, inflammation, and motility, with consequences on the quality of life. Limited evidences showed a potential involvement of gut fungal communities. Here, the gut bacterial and fungal microbiota of a cohort of IBS patients have been characterized and compared with that of healthy subjects (HS). The IBS microbial community structure differed significantly compared to HS. In particular, we observed an enrichment of bacterial taxa involved in gut inflammation, such as Enterobacteriaceae, Streptococcus, Fusobacteria, Gemella, and Rothia, as well as depletion of health-promoting bacterial genera, such as Roseburia and Faecalibacterium. Gut microbial profiles in IBS patients differed also in accordance with constipation. Sequence analysis of the gut mycobiota showed enrichment of Saccharomycetes in IBS. Culturomics analysis of fungal isolates from feces showed enrichment of Candida spp. displaying from IBS a clonal expansion and a distinct genotypic profiles and different phenotypical features when compared to HS of Candida albicans isolates. Alongside the well-characterized gut bacterial dysbiosis in IBS, this study shed light on a yet poorly explored fungal component of the intestinal ecosystem, the gut mycobiota. Our results showed a differential fungal community in IBS compared to HS, suggesting potential for new insights on the involvement of the gut mycobiota in IBS. Key points • Comparison of gut microbiota and mycobiota between IBS and healthy subjects • Investigation of cultivable fungi in IBS and healthy subjects • Candida albicans isolates result more virulent in IBS subjects compared to healthy subjects

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results